Thrombosis and COVID-19 vaccines
Vaccines against COVID-19 from Moderna Biotech Spain, SL (COVID-19 Vaccine Moderna – mRNA technology), AstraZeneca (Oxford/Astrazeneca Vaccine - ChAdOx1 - adenovirus vector technology) and Janssen-Cilag International NV (COVID-19 Vaccine) Janssen - Ad.26.COV2.S - adenovirus vector technology) used i...
| Autores: | , , |
|---|---|
| Formato: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | Brasil |
| Recursos: | Hospital de Clínicas de Itajubá |
| Repositorio: | Revista Ciências em Saúde |
| Idioma: | inglés portugués |
| OAI Identifier: | oai:ojs.portalrcs.hcitajuba.org.br:article/1165 |
| Acesso em linha: | https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1165 |
| Access Level: | acceso abierto |
| Palavra-chave: | COVID-19 vaccines vacinas |
| Resumo: | Vaccines against COVID-19 from Moderna Biotech Spain, SL (COVID-19 Vaccine Moderna – mRNA technology), AstraZeneca (Oxford/Astrazeneca Vaccine - ChAdOx1 - adenovirus vector technology) and Janssen-Cilag International NV (COVID-19 Vaccine) Janssen - Ad.26.COV2.S - adenovirus vector technology) used in Europe, the United States and Brazil has presented severe thrombotic adverse reactions. The recorded thrombosis occurred in unusual sites, such as the sagittal venous sinus. |
|---|